NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:NRSN • IL0011809592

1.0188 USD
0 (-0.12%)
Last: Feb 11, 2026, 03:51 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

NRSN Key Statistics, Chart & Performance

Key Statistics
Market Cap30.26M
Revenue(TTM)N/A
Net Income(TTM)-10.21M
Shares29.70M
Float23.30M
52 Week High2.6
52 Week Low0.68
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.54
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2021-12-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
NRSN short term performance overview.The bars show the price performance of NRSN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

NRSN long term performance overview.The bars show the price performance of NRSN in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of NRSN is 1.0188 USD. In the past month the price decreased by -0.97%. In the past year, price decreased by -11.69%.

NEUROSENSE THERAPEUTICS LTD / NRSN Daily stock chart

NRSN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to NRSN. When comparing the yearly performance of all stocks, NRSN is a bad performer in the overall market: 73.5% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
NRSN Full Technical Analysis Report

NRSN Financial Highlights

Over the last trailing twelve months NRSN reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 25.92% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1037.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-292.8%
Sales Q2Q%N/A
EPS 1Y (TTM)25.92%
Revenue 1Y (TTM)N/A
NRSN financials

NRSN Forecast & Estimates

10 analysts have analysed NRSN and the average price target is 10.37 USD. This implies a price increase of 917.86% is expected in the next year compared to the current price of 1.0188.


Analysts
Analysts80
Price Target10.37 (917.86%)
EPS Next Y32.63%
Revenue Next YearN/A
NRSN Analyst EstimatesNRSN Analyst Ratings

NRSN Ownership

Ownership
Inst Owners0.94%
Ins Owners13.78%
Short Float %2.46%
Short Ratio1.7
NRSN Ownership

NRSN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.21393.136B
AMGN AMGEN INC16.27196.357B
GILD GILEAD SCIENCES INC17.47182.665B
VRTX VERTEX PHARMACEUTICALS INC22.63117.594B
REGN REGENERON PHARMACEUTICALS16.7779.341B
ALNY ALNYLAM PHARMACEUTICALS INC48.0342.669B
INSM INSMED INC N/A31.681B
NTRA NATERA INC N/A29.21B
BIIB BIOGEN INC12.5727.736B
UTHR UNITED THERAPEUTICS CORP16.1420.376B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About NRSN

Company Profile

NRSN logo image Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Company Info

NEUROSENSE THERAPEUTICS LTD

11 Hamenofim St., Building B

Herzliya IL

Employees: 15

NRSN Company Website

NRSN Investor Relations

Phone: 97297996183

NEUROSENSE THERAPEUTICS LTD / NRSN FAQ

Can you describe the business of NEUROSENSE THERAPEUTICS LTD?

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease


What is the stock price of NEUROSENSE THERAPEUTICS LTD today?

The current stock price of NRSN is 1.0188 USD. The price decreased by -0.12% in the last trading session.


Does NEUROSENSE THERAPEUTICS LTD pay dividends?

NRSN does not pay a dividend.


What is the ChartMill rating of NEUROSENSE THERAPEUTICS LTD stock?

NRSN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Which stock exchange lists NRSN stock?

NRSN stock is listed on the Nasdaq exchange.


What sector and industry does NEUROSENSE THERAPEUTICS LTD belong to?

NEUROSENSE THERAPEUTICS LTD (NRSN) operates in the Health Care sector and the Biotechnology industry.


What is the outstanding short interest for NEUROSENSE THERAPEUTICS LTD?

The outstanding short interest for NEUROSENSE THERAPEUTICS LTD (NRSN) is 2.46% of its float.